Kedrion Biopharma Strengthens Industry Connections at IgNS 2026 Conference

Kedrion Biopharma, a prominent player in the field of plasma-derived therapies, showcased its commitment to advancing immunoglobulin therapies during its participation in the Immunoglobulin National Society (IgNS) 2026 Conference in Las Vegas. The event, held from October 15 to 18, 2026, marked a significant gathering of professionals from various sectors of the immunoglobulin community.

The conference served as a vital platform for Kedrion Biopharma to engage in meaningful discussions about the evolving therapy landscape accompanying its extensive immunoglobulin product portfolio, which includes notable products like QIVIGY®, YIMMUGO®, and GAMMAPLEX®. Bob Rossilli, Chief Commercial Officer of Kedrion Biopharma, highlighted the importance of this forum, stating, "Immunoglobulin therapies are central to Kedrion's commitment to serving patients, and IgNS provides an important forum to bring together the clinical, policy, payer, and market perspectives shaping this field."

Kedrion's involvement at IgNS 2026 encompassed scientific presentations that covered its portfolio of intravenous immunoglobulin (IVIG) products. Eva Gonzalez, Senior Director of Medical Affairs for the U.S., Canada, and LATAM regions, emphasized the necessity of scientific exchange, stating, "This exchange is essential to advancing immunoglobulin therapy because it allows us to translate data into insights that can inform clinical practice and deepen our understanding of how treatment fits into patients' lives."

The company's presentations featured various scientific posters that shed light on key studies related to immunoglobulin therapies:
1. Analysis of Infusion Rates and Infusional Adverse Events: This clinical trial study examined the response to a new 10% intravenous immunoglobulin in patients with primary immunodeficiency.
2. Non-Serious Infections During a Clinical Trial: This poster focused on observations related to non-serious infections among participants receiving a 10% IVIg treatment.
3. Real-world Evaluation of Immunoglobulin Efficacy: A study assessing the tolerability and clinical outcomes in patients with secondary immunodeficiency.
4. Intravenous Immune Globulin Outcomes Analysis: A retrospective examination of 10% IVIg use in patients with nonfamilial hypogammaglobulinemia.
5. Review of IVIG Therapy in Kidney Transplant Recipients: A retrospective analysis investigating the effects of IVIG therapy in individuals who underwent kidney transplants.

Kieu Nguyen, Medical Science Liaison in Immunology at Kedrion, pointed out that the findings from these posters contribute to a broader understanding of the applications of immunoglobulin therapies. He reiterated the importance of continued investigation that analyzes how these treatments affect different patient populations.

Alongside the scientific presentations, Kedrion's leadership team participated in significant conference programs. Duccio Manetti, Chief Communications and Government Affairs Officer, co-chaired the Executive Business Forum on the first day of the event with Karmen Stowe from AOM Infusion. This forum aimed to unite varying perspectives on public policy, payer dynamics, clinical management, and research trends that are instrumental in shaping the future of immunoglobulin therapies.

In tandem with these discussions, Kedrion hosted a satellite symposium on October 17, featuring Dr. Sam Ahn from North Bay Allergy and Asthma Associates. This presentation focused on the efficacy, tolerability, and infusion outcomes related to Kedrion's latest IVIG product.

Kedrion Biopharma not only shared scientific evidence but also communicated its vision as a leader in the biopharmaceutical industry. As they displayed their dedication to innovation, it becomes clear that Kedrion is driven to improve patient outcomes through targeted therapies designed for rare and serious diseases. With a portfolio encompassing 39 products across more than 100 countries, Kedrion stands as the fifth-largest global contributor in the plasma-derived products arena.

The IgNS 2026 Conference provided a robust environment for Kedrion Biopharma to reinforce its commitment to enhancing immunoglobulin therapy, advancing understanding, and fostering collaboration across the healthcare community. The company is dedicated to creating a future where scientific innovation and quality care remain intrinsic to the patient care journey.

For further information on Kedrion Biopharma's initiatives, including their innovative product offerings and upcoming events, interested parties can visit their official website at www.kedrion.com.